// COMPANY
Merck KGaA
SECTOR PHARMACEUTICALSMENTIONS 1LAST SEEN OCTOBER 19, 2026
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
m_and_a·Axios Pro Rata·OCTOBER 19, 2026
“Merck KGaA agreed to buy U.K. cancer biotech Silence Therapeutics (Nasdaq: SLN) for around $1.1b in cash, or $20 per share (130% premium to Friday's close).”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.